Shankland S J, Floege J, Thomas S E, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry D M, Johnson R J, Couser W G
Department of Nephrology, University of Washington, Seattle, USA.
Kidney Int. 1997 Aug;52(2):404-13. doi: 10.1038/ki.1997.347.
The inadequate proliferative response of the visceral glomerular epithelial cell (GEC) following injury in vivo may contribute to the development of progressive glomerulosclerosis in many forms of glomerular disease. Cell proliferation is ultimately controlled by cell-cycle regulatory proteins, including cyclins that bind to cyclin dependent kinases (CDK), and the active complex formed is necessary for progression through the cell-cycle. By inhibiting cyclin-CDK complexes, cyclin kinase inhibitors arrest the cell-cycle and prevent proliferation. To determine the mechanisms that may be responsible for the lack of GEC proliferation in vivo, we examined GEC expression of specific cell-cycle proteins in normal rats and in the passive Heymann nephritis (PHN) model of membranous nephropathy, where the GEC are the target of complement-mediated injury. Following antibody deposition and complement activation there was a marked up-regulation in the cyclin kinase inhibitors p21 and p27 in rats with PHN. By associating with cyclin A-CDK2 complexes, p21 and p27 limited the kinase activity of CDK2. Giving bFGF to rats with PHN was associated with an increase in GEC mitosis and ploidy and a decrease in expression of p21, but not CDK2 or p27. Furthermore, apoptosis was not present in PHN, but was increased in rats given bFGF. In conclusion, this study shows that the low proliferative capacity of the GEC in vivo in response to immune injury may be due to an increase in the expression of specific cyclin kinase inhibitors. The increase in mitosis in PHN rats given bFGF may be due to a decrease in p21. Thus, changes in cell cycle regulatory proteins may regulate the response of GEC to injury and underlie the development of progressive glomerulosclerosis in diseases of the GEC.
体内损伤后内脏肾小球上皮细胞(GEC)增殖反应不足可能导致多种形式的肾小球疾病发展为进行性肾小球硬化。细胞增殖最终受细胞周期调节蛋白控制,包括与细胞周期蛋白依赖性激酶(CDK)结合的细胞周期蛋白,形成的活性复合物是细胞周期进展所必需的。细胞周期蛋白激酶抑制剂通过抑制细胞周期蛋白 - CDK复合物来阻止细胞周期并防止增殖。为了确定体内GEC增殖缺乏可能的机制,我们检测了正常大鼠和膜性肾病被动海曼肾炎(PHN)模型中特定细胞周期蛋白的GEC表达,在该模型中GEC是补体介导损伤的靶点。抗体沉积和补体激活后,PHN大鼠中细胞周期蛋白激酶抑制剂p21和p27显著上调。通过与细胞周期蛋白A - CDK2复合物结合,p21和p27限制了CDK2的激酶活性。给PHN大鼠注射碱性成纤维细胞生长因子(bFGF)与GEC有丝分裂和倍体增加以及p21表达降低有关,但与CDK2或p27无关。此外,PHN中不存在细胞凋亡,但在给予bFGF的大鼠中细胞凋亡增加。总之,本研究表明,体内GEC对免疫损伤的低增殖能力可能是由于特定细胞周期蛋白激酶抑制剂表达增加所致。给予bFGF的PHN大鼠有丝分裂增加可能是由于p21减少。因此,细胞周期调节蛋白的变化可能调节GEC对损伤的反应,并成为GEC疾病中进行性肾小球硬化发展的基础。
Cell Growth Differ. 1996-2
Am J Physiol Renal Physiol. 2024-4-1
J Cell Commun Signal. 2022-9
J Mol Med (Berl). 2017-10-16
Cell Cycle. 2016-7-17
Sci Rep. 2016-2-15
BMC Mol Biol. 2015-2-12
Front Endocrinol (Lausanne). 2015-2-23